Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



FDA Agrees to Speed Review of Ariad Drug

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

The FDA has agreed to an accelerated review of Ariad Pharmaceuticals' (Nasdaq: ARIA  ) leukemia drug ponatinib, the company announced Wednesday. The FDA has established an action date of March 27, the company said.

The FDA accepted Ariad's request to launch a "priority review," which the FDA uses to shorten the review time for drugs that could provide significant improvements in treatment of diseases. Ponatinib is aimed at treating chronic myeloid leukemia and acute lymphoblastic leukemia, doing so by inhibiting an abnormality known as BCR-ABL.

Ponatinib will face competition from other leukemia drugs on the market, including products from Novartis (NYSE: NVS  ) and Bristol-Myers Squibb (NYSE: BMY  ) . Competition and questions  about approval spurred an analyst at Oppenheimer & Co. to downgrade Ariad earlier this week from "outperform" to "perform." The analyst also raised his price target to $23.

The Boston Globe quoted CEO Harvey Berger as saying: "We're launch-ready as we stand here today. Whenever the approval comes, we have the sales and distribution force, the manufacturing people, the medical liaisons, all the people we need to commercialize successfully."

Dan Carroll has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2076425, ~/Articles/ArticleHandler.aspx, 10/20/2016 5:55:49 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,162.35 -40.27 -0.22%
S&P 500 2,141.34 -2.95 -0.14%
NASD 5,241.83 -4.58 -0.09%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/20/2016 4:00 PM
ARIA $10.78 Down -0.03 -0.28%
Ariad Pharmaceutic… CAPS Rating: **
BMY $50.36 Up +0.49 +0.98%
Bristol-Myers Squi… CAPS Rating: ****
NVS $75.92 Up +0.27 +0.36%
Novartis CAPS Rating: ****